Ultrasmall Confined Iron Oxide Nanoparticle MSNs as a pH‐Responsive Theranostic Platform
Source abstract
Abstract
A unique mesoporous silica nanoparticles (MSNs)‐based theranostic platform with ultrasmall iron oxide nanoparticles (NPs) confined within mesopore network has been developed by a facile but efficient physical‐vapor‐infiltration (PVI) method. The highly dispersed Fe species within mesopore channels can synchronously function as the non‐toxic contrast agents for highly efficient T1‐weighted MR imaging, and as anchoring sites for anti‐cancer drug molecule loading and pH‐responsive release based on the special metal‐ligand coordination bonding between the Fe species and drug molecules. Moreover, the obtained Fe‐MSNs exhibit favorable biocompatibility, enhanced chemotherapeutic efficacy and concurrently diminished side effects due to the non‐specific attack of chemotherapeutic drugs, as well as the capability in circumventing the multidrug resistance (MDR) of cancer cells and suppressing the metastasis of tumor cells in vitro and in vivo. This pH‐resoponsive theranostic agent provides a new promising MSNs‐based anti‐cancer nanomedicine for future biomedical application.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanopore and Nanochannel Transport Studies · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of High Performance Ceramics and Superfine Microstructure Shanghai Institute of Ceramics Chinese Academy of Sciences 1295 Ding‐Xi Road Shanghai 200050 PR China
Shanghai Institute of Materia Medica Chinese Academy of Sciences 501 Haike Road Shanghai 201203 PR China
Department of Radiology Cancer Hospital/Institute & Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 PR China
References (55)
Show source-provided references
1. 10.1002/adma.20110231310.1002/adma.201102313 ↗
2. 10.1016/j.jconrel.2012.07.04510.1016/j.jconrel.2012.07.045 ↗
3. 10.1021/mp100228v10.1021/mp100228v ↗
4. 10.1146/annurev.bi.55.070186.00331110.1146/annurev.bi.55.070186.003311 ↗
5. Tannock I. F. · Cancer Res. · 1989 · 49 · 4373
6. 10.1021/ja065485r10.1021/ja065485r ↗
7. 10.1002/adma.20030516510.1002/adma.200305165 ↗
8. 10.1021/la063415s10.1021/la063415s ↗
9. 10.1021/ja203340u10.1021/ja203340u ↗
10. 10.1002/adfm.20110176610.1002/adfm.201101766 ↗
11. Pinho S. L. · Biomaterials · 2012 · 33 · 92510.1016/j.biomaterials.2011.09.086 ↗
12. 10.1021/ja108409510.1021/ja1084095 ↗
13. 10.1002/anie.20060477510.1002/anie.200604775 ↗
14. 10.1021/ja710193c10.1021/ja710193c ↗
15. 10.1002/smll.20110047210.1002/smll.201100472 ↗
16. 10.1016/j.nucmedbio.2009.08.00610.1016/j.nucmedbio.2009.08.006 ↗
17. 10.1002/smll.20100084710.1002/smll.201000847 ↗
18. 10.1063/1.356045110.1063/1.3560451 ↗
19. 10.1002/anie.20050150010.1002/anie.200501500 ↗
20. 10.1021/nn901398j10.1021/nn901398j ↗
21. 10.1021/nn101511710.1021/nn1015117 ↗
22. 10.1038/ncpneph066010.1038/ncpneph0660 ↗
23. 10.1016/j.biomaterials.2011.11.08610.1016/j.biomaterials.2011.11.086 ↗
24. 10.1021/nl102623x10.1021/nl102623x ↗
25. 10.1039/c1cc13416g10.1039/c1cc13416g ↗
26. 10.1002/mrm.2047710.1002/mrm.20477 ↗
27. 10.1063/1.47843510.1063/1.478435 ↗
28. 10.1088/0957-4484/22/24/24560410.1088/0957-4484/22/24/245604 ↗
29. 10.1021/nl902715v10.1021/nl902715v ↗
30. 10.1016/j.molcata.2006.12.02710.1016/j.molcata.2006.12.027 ↗
31. 10.1021/jp312820g10.1021/jp312820g ↗
32. 10.1016/j.micromeso.2011.11.01110.1016/j.micromeso.2011.11.011 ↗
33. 10.1039/c2ra20380d10.1039/c2ra20380d ↗
34. 10.1016/j.ccr.2013.03.00710.1016/j.ccr.2013.03.007 ↗
35. 10.1021/ja067379v10.1021/ja067379v ↗
36. 10.1021/ja991400t10.1021/ja991400t ↗
37. 10.1109/TMAG.1978.105991810.1109/TMAG.1978.1059918 ↗
38. 10.1021/jp075133m10.1021/jp075133m ↗
39. 10.1021/ie201894c10.1021/ie201894c ↗
40. 10.1016/j.tsf.2008.09.08610.1016/j.tsf.2008.09.086 ↗
41. 10.1021/jp203799m10.1021/jp203799m ↗
42. 10.1039/c0jm00022a10.1039/c0jm00022a ↗
43. 10.1002/anie.20060340410.1002/anie.200603404 ↗
44. 10.1021/ja810011p10.1021/ja810011p ↗
45. 10.1021/ja901015710.1021/ja9010157 ↗
46. 10.1007/978-0-387-74039-3_110.1007/978-0-387-74039-3_1 ↗
47. 10.1038/nrc329710.1038/nrc3297 ↗
48. 10.1038/nrd237210.1038/nrd2372 ↗
49. 10.1007/BF0069059910.1007/BF00690599 ↗
50. 10.2174/09298671179483919710.2174/092986711794839197 ↗
51. 10.1016/j.cell.2004.06.00610.1016/j.cell.2004.06.006 ↗
52. 10.1158/0008-5472.CAN-08-190210.1158/0008-5472.CAN-08-1902 ↗
53. Joki T. · Cancer Res. · 2000 · 60 · 4926
54. 10.1016/j.nano.2011.08.01910.1016/j.nano.2011.08.019 ↗
55. 10.1021/nn100448z10.1021/nn100448z ↗